EN DE
Watch Biogen Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Biogen Inc (BIIB) fair value: what the stock is really worth

As of Nov 5, 2026: fair value (intrinsic value) of Biogen Inc stock $268, price $244, upside +9.8%, quality 62 out of 100. Rating: fairly valued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

BI Biogen Inc logo Some data Nov 5, 2026

Biogen Inc

BIIB · US
Fairly valued, in an uptrend

The stock costs about what our calculation considers fair.

Quality 62/100
Low debt
Generates free cash flow
Positive coverage
Fair value $267.83 · Fairly valued (+9.8%)
Thin margins · 8.3% net margin (TTM)
Mixed vs. peers (6/14)
Moderate moat 53/100 · thin data
Insiders sold $239,750 (6M)
Some data
Weak Growth (revenue 5y −6.1 %/yr in USD)

Risks from the AI analysis

🚩AI could accelerate rival drug discovery🚩Generics and biosimilars could cut MS drug sales
Watch Biogen Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$349.79 $113.38 Fair Value $267.83 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.

How to read this chart

60‑month range $113.38 – $349.79 · fair‑value band $191.44 – $340.49 · the $243.93 price screens below the $267.83 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 5, 2026.

Follow Biogen in your weekly email

Every Wednesday you see whether Biogen is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.

Show moreShow less

The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies.

Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Stock analysis

Biogen Inc (BIIB) currently trades at $243.93, while our model-based Fair Value estimate is $267.83, so the stock looks roughly fairly valued today (gap 8.9%).

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $220.80 per share, and 4 of the 24 models we run sit above the $243.93 price.

Bear case: the Earnings-Based group reads lowest at $69.68, and 20 of the 24 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $191.44 (bear) to $340.49 (bull), the price of $243.93 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 62/100 (solid quality), in the Healthcare sector.

Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.

Biogen Inc reported revenue of $9.8B in FY2025 versus $11.0B in FY2021, a compound −2.8%/yr. Reported net income was $1.3B in FY2025, compounding −4.5%/yr from FY2021.

Key figures

Market cap $36.3B Large · P/E ratio 43.3 · P/S ratio 3.62 · EPS (TTM) $5.63 · Net margin 8.3% · Return on equity 4.6% · Return on assets (EBIT) 9.3% · Operating margin 25.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 53 out of 100 (low confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 4% below its 52-week high and 59% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at 10%, BIIB screens cheaper than that median.

Fair Value models

Bear $191.44 Fair Value $267.83 Bull $340.49
Price $243.93 · Upside +9.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($4.78 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $177.63 $317.50 $560.62 77
Growth DCF $181.26 $304.11 $503.44 76
5Y EBITDA Exit $157.41 $273.46 $410.81 74
All 24 models by family
DCF Models
FCF DCF $177.63 $317.50 $560.62 77
Owner Earnings $74.92 $142.89 $261.05 73
5Y Revenue Exit $117.31 $196.44 $297.60 71
5Y EBITDA Exit $157.41 $273.46 $410.81 74
5Y P/E Exit $130.00 $220.80 $317.49 70
10Y Revenue Exit $131.67 $212.04 $321.58 66
10Y EBITDA Exit $162.55 $268.64 $414.01 67
10Y P/E Exit $144.14 $229.94 $337.82 63
Earnings-Based
Graham-Dodd $59.52 $209.01 $281.13 64
Lynch FV $48.78 $69.68 $90.58 61
PEG = 1.0 $48.78 $69.68 $90.58 57
EPV $97.24 $119.42 $139.43 74
Multiples
P/E Multiple $144.44 $192.58 $240.73 63
P/S Multiple $111.61 $148.81 $186.02 58
P/B Multiple $59.10 $78.80 $98.50 55
EV/EBIT $135.35 $189.36 $243.36 66
EV/EBITDA $162.18 $225.13 $288.08 67
EV/Revenue $88.97 $138.53 $188.08 53
Asset-Based
NCAV (Graham) $8.76 $11.73 $17.51 54
Growth DCF
Growth DCF $181.26 $304.11 $503.44 76
Rev-Margin DCF $117.31 $197.07 $292.27 72
Economic Profit
Residual Income $103.51 $110.21 $123.05 71
ROIC Compounder $97.24 $119.42 $161.51 72
Growth Earnings
Growth-Adj P/E $124.02 $177.17 $230.32 67

The fair value above starts from this blend and is adjusted for a year distorted by one-off effects.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 62/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 38
How much profit the company makes from its sales and capital
Quality Growth 32
Are margins and returns getting better?
Cashflow 86
Do the profits arrive as real cash?
Financial strength 72
Debt, balance sheet and risk of trouble
Investment 72
Does it invest with discipline instead of growing at any price?
Low Volatility 79
How calm the share price moves, does not count
Price momentum 79
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 95
Distance to the 52-week high, does not count
New shares 71
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director sold shares worth $239,750 and none bought.

  • SaleLloyd MinorDirector1,186 shares at $202.15$239,750Aug 4, 202610b5-1 plan
  • BuyNicole MurphyHead of Pharm Ops and Tech3 shares at $195.04$585Feb 12, 2026
  • SalePriya SinghalHead of Development2× since Feb 2, 2026: 3,408 shares, avg. $195.32$665,664Feb 9, 202610b5-1 plan

Plus 11 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 5, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
+1.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.1%
Start year 2020 (pandemic). Over 10 years: −0.9% a year
Revenue growth 40 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.6%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−18.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−18.7%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−18.7% vs −5.4%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.34% → 19%
Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

Price in line with expectations
The price assumes more growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+4.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+2.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +2.4% a year for the price and +0.5% for the forecasts.
Forecast 2026 (sales)+6.9%
Forecast 2027 (sales)+1.9%
Projected 2028 (sales)+1.9%
Projected 2029 (sales)+1.9%
Projected 2030 (sales)+2.0%

Watch BIIB, get fair value alerts →

Recent news

News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.
Note from the team Oct 11, 2026
AI conclusion: Moderate margins point to a potential moat, yet typical biotech innovation risks and regulatory scrutiny on approvals limit any clear signals of durable quality.
Main risk: Smaller biotechs with access to AI platforms for target identification and molecule design might develop neurological treatments faster than Biogen, intensifying competition for its pipeline assets and pressuring future margins.
Bull case: Biogen could integrate AI tools across its own research and clinical processes to shorten development timelines and strengthen its pipeline against faster-moving competitors.
Bear case: If AI-enabled rivals advance competing therapies while legacy multiple sclerosis revenues continue to erode, Biogen might struggle to replace declining sales with new products and face sustained margin pressure.
Biogen's latest 52-week data show litifilimab producing further gains in skin clearance for cutaneous lupus patients after the first 24 weeks. This pipeline candidate could help shift the business away from its older multiple sclerosis franchise. Will the lupus program move forward fast enough on its own to matter, or will other late-stage assets have to deliver most of the growth?
Join the discussion →

Compare Biogen Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 74 stocks

Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 62 · Above median
Fair Value upside +9.8% · Above median
Profitability
Return on equity (12 months) 4.6% · Below median
Return on assets 4.4% · Below median
Net margin (12 months) 8.3% · Below median
Operating margin (12 months) 25.1% · Above median
Growth and dividend
Revenue growth (quarter YoY) 3.4% · Below median
Balance sheet
Debt / equity 0.34× · Above median

Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper

P/E (12 months) 43.3× · Priciest 25%
P/B 1.99× · Cheaper than median
P/S (12 months) 3.62× · Pricier than median
Price / free cash flow (fiscal year) 17.7× · Cheaper than median
EV/EBITDA 11.8× · Cheaper than median
PEG 2.61× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)46 · sector 20
FUTURE (revenue growth)17 · sector 34
PAST (return on equity)18 · sector 41
HEALTH (low debt)83 · sector 93
DIVIDEND (yield)0 · sector 38

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Bristol-Myers Squibb Company BMY $63.13 $75.91 +20% vs BIIB
Gilead Sciences, Inc GILD $167.57 $191.93 +15% vs BIIB
Amgen Inc AMGN $460.28 $507.39 +10% vs BIIB
AbbVie Inc ABBV $288.24 $259.62 −10% vs BIIB
Novartis AG NOVN CHF 134.12 CHF 119.58 −11% vs BIIB
Merck & Co MRK $146.94 $129.26 −12% vs BIIB
Pfizer Inc PFE $29.88 $24.87 −17% vs BIIB
Roche Holding RO CHF 399.00 CHF 326.56 −18% vs BIIB
Johnson & Johnson, JNJ $272.32 $168.85 −38% vs BIIB
Eli Lilly and Company LLY $1,365 $749.92 −45% vs BIIB

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Biogen Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Biogen Inc Fair Value". https://www.fairvalue-calculator.com/stock/BIIB

Frequently asked questions

Is Biogen Inc (BIIB) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of $267.83 versus a price of $243.93, about +10% upside (fairly valued).
What is the fair value of BIIB?
Our model-based fair value for Biogen Inc is $267.83 (as of Nov 5, 2026), built from audited fundamentals. The current price: $243.93.
What is the quality score of BIIB?
Biogen Inc has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Biogen Inc (BIIB)?
Our model-based price target is the fair value of $267.83 (as of Nov 5, 2026) from 24 valuation models. Cautious scenario $191.44, optimistic scenario $340.49. It is a calculation from audited fundamentals, not an analyst target.
What is the Biogen Inc stock forecast for 2026?
Our models put fair value at $267.83, about +10% upside versus a price of $243.93 (fairly valued). Cautious scenario $191.44, optimistic scenario $340.49. The calculation is refreshed regularly with new filings.
What is the revenue of Biogen Inc (BIIB)?
Biogen Inc reported trailing-twelve-month revenue of about $10.0B (latest available figure, as of Nov 5, 2026).
What growth is priced into Biogen Inc (BIIB)?
For today's price to be fair in a discounted-cash-flow model, Biogen Inc would have to grow free cash flow by +4.8 % per year for five years (discount rate 8.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -6.1 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of BIIB use?
Our models discount Biogen Inc at 8.1 %: a base by market capitalisation (large), damped by beta 0.09, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Biogen Inc that is +4.8 % per year a year over ten years, using the same discount rate (8.1 %) and the same formula as our fair value.
How much growth has Biogen Inc (BIIB) delivered so far?
Over the past 5 years revenue at Biogen Inc grew -6.1 % a year. The price currently implies +4.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Biogen Inc (BIIB) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Biogen Inc (+4.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Biogen Inc (BIIB)?
The free-cash-flow yield on the price is 5.65 %: that much free cash flow Biogen Inc produces per unit of market value. When it exceeds the discount rate of our models (8.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Biogen Inc (BIIB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Biogen Inc it is $267.83 per share (as of Nov 5, 2026), against a price of $243.93. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Biogen Inc stock overvalued or undervalued in 2026?
As of Nov 5, 2026, BIIB trades below its calculated fair value: price $243.93, fair value $267.83, a gap of about +10% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BIIB?
No. The price is what the market pays today ($243.93); the fair value is what the company's own numbers justify ($267.83). For Biogen Inc the two are $23.90 per share apart. That gap is exactly why we show both numbers side by side.
How much is Biogen Inc worth?
The market values Biogen Inc at about $36.3B (market capitalisation, as of Nov 5, 2026). Per share that is $243.93; our models calculate a fair value of $267.83 per share.
What do the bullish and bearish scenarios say about BIIB?
Our models span a range for Biogen Inc: cautious scenario $191.44, base $267.83, optimistic $340.49 per share (as of Nov 5, 2026, price $243.93). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BIIB?
Biogen Inc trades at a price-to-earnings ratio of 43.3 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $267.83 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 15.4. Other multiples: PEG 2.6, P/B 2.0, P/S 3.6, EV/EBITDA 11.8.
What is the PEG ratio of BIIB?
The PEG ratio of Biogen Inc is 2.61 (P/E divided by earnings growth, as of Nov 5, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Biogen Inc (BIIB)?
Balance-sheet figures for Biogen Inc (as of Nov 5, 2026): return on equity 4.6%, debt of 0.34 per unit of equity. They feed the Quality Score of 62/100, which measures business quality independently of the share price.
How far is BIIB from its 52-week high?
Biogen Inc trades at $243.93, about 4% below its 52-week high of $254.46 and 59% above the low of $153.43 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of $267.83 is for.
Which stocks are comparable to Biogen Inc?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Biogen Inc stock attractive at the current price?
The data as of Nov 5, 2026: price $243.93, calculated fair value $267.83 (+10%), Quality Score 62/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BIIB calculated?
We run Biogen Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $267.83, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. Biogen Inc currently trades 9% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Biogen Inc (BIIB)?
The closing price on Nov 5, 2026 was $243.93. Our model-based fair value is $267.83, about +10% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Biogen Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Where does the earnings growth of Biogen Inc (BIIB) come from?
Earnings per share at Biogen Inc grew −5.0 % a year from 2014 to 2025. Broken into its drivers: revenue per share +4.1 %, EBIT margin −7.4 %, tax rate +1.9 %, residual (interest, one-offs) −3.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Biogen Inc

How large is the market capitalisation of Biogen Inc (BIIB)?
The market capitalisation of Biogen Inc is $36.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Biogen Inc (BIIB)?
The price-to-sales ratio of Biogen Inc is 3.62 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Biogen Inc (BIIB)?
Earnings per share at Biogen Inc are $5.63 (price ÷ EPS = P/E 43.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Biogen Inc (BIIB)?
The net margin of Biogen Inc is 8.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Biogen Inc (BIIB)?
The return on equity (ROE) of Biogen Inc is 4.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Biogen Inc (BIIB)?
On an EBIT basis the return on assets of Biogen Inc is 9.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Biogen Inc (BIIB)?
The operating margin of Biogen Inc is 25.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Biogen Inc (BIIB)?
Revenue at Biogen Inc is growing +3.4% versus a year earlier (3y avg −1.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Biogen Inc (BIIB)?
Earnings per share at Biogen Inc are growing −84.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Biogen Inc (BIIB) carry?
The net debt of Biogen Inc is $3.9B (fiscal year 2025, ≈ 1.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Biogen Inc in the live analysis

One click puts Biogen Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.